



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Otlertuzumab

Cat. No.:	HY-P99212
CAS No.:	1372645-37-8
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research <sup>[1]</sup> .
IC <sub>50</sub> & Target	CD37 <sup>[1]</sup>
In Vitro	Otlertuzumab (TRU-016) in combination with <a href="#">Rituximab</a> (HY-P9913), <a href="#">Rapamycin</a> (HY-10219), or <a href="#">Bendamustine</a> (HY-13567) increases cell killing of NHL cells <sup>[2]</sup> . Otlertuzumab has the ability to bind to and kill CD37 <sup>+</sup> cells <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Otlertuzumab (TRU-016) in combination with <a href="#">Bendamustine</a> (HY-13567) displays greater anti-tumor activity than either agent alone against a follicular lymphoma tumor model in SCID mice <sup>[2]</sup> . Otlertuzumab shows significant antitumor activity in mice bearing Ramos or Daudi tumor xenografts <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Byrd JC, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. *Blood*. 2014 Feb 27;123(9):1302-8.
- [2]. Baum P R, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, 2009, 27(15\_suppl): 8571-8571.
- [3]. Cervený C G, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. *Journal of Clinical Oncology*, 2008, 26(15\_suppl): 3074-3074.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA